Fund moves
3.5%Stake
The holder reported owning less than 5%, which ends its duty to keep reporting this stake.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
OVID · NASDAQ · Pharmaceutical Preparations
Ovid Therapeutics (OVID) · oqro.io/stocks/OVID · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
No open-market purchase by an insider of Ovid Therapeutics was filed in the last 90 days. The latest on record was on Jan 29, 2025.
Since 2017, Ovid Therapeutics insiders reported 10 open-market purchases and 6 sales on Forms 4 and 5, with purchases in 6 different years, most recently 2025.
No open-market sale by an insider of Ovid Therapeutics (OVID) was filed with the SEC in the last 90 days.
No trade in Ovid Therapeutics (OVID) was disclosed by a member of Congress in the last 12 months.
Ovid Therapeutics's next results are expected on Mar 16, 2027, after the market closes. The date can move until the company confirms it. Insiders often trade in the weeks right after results.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
$2.20−0.14 (−5.98%)
Close of Nov 20, 2026, vs Nov 19 · end-of-day
+80.3% (+$0.98) from Nov 20, 2025 to Nov 20, 2026 · adjusted daily closes
Adjusted close went from $1.22 on Nov 20, 2025 to $2.20 on Nov 20, 2026 (+80.3%). Disclosed in this range: 0 insider trades, 2 pre-arranged insider sales, 0 Congress trades, and 3 13F position changes for 2 quarters ending in it.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Pharmaceutical Preparations company based in New York, Ny.
Last 12 months
+80.3%
Market value
$415M
S&P 500 +5.7% over the same dates. Prices adjusted for splits and dividends.
Short interest: 18.1M shares sold short (9.6% of shares outstanding), +0.4% vs the previous count, 8.2 days of normal trading to buy them back. FINRA, as of Oct 30, 2026. Short interest history
Revenue, fiscal 2025
$7.25M
+1181.3% vs the year before
Net income, fiscal 2025
−$17.4M
A loss for the year
Shares outstanding
189M
As of Nov 4, 2026
Fund moves
The holder reported owning less than 5%, which ends its duty to keep reporting this stake.
Fund moves
From a 13F filed Aug 14, 2026 covering holdings at Jun 30, 2026 — a quarter-end snapshot, not a live trade.
Fund moves
From a 13F filed Aug 14, 2026 covering holdings at Jun 30, 2026 — a quarter-end snapshot, not a live trade.
Fund moves
From a 13F filed May 15, 2026 covering holdings at Mar 31, 2026 — a quarter-end snapshot, not a live trade.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Top officer leaving
“Rona’s departure, the Company’s Board of Directors (the “Board”) appointed Charles Carter, the Company’s Senior Vice President of Finance and Financial Planning, as the Company’s Chief Financial Officer, principal financial officer, principal accounting officer and secretary, effective as of the Separation Date.”
8-K on sec.govFrom the company's 8-K, 10-K and 10-Q filings over the last two years. A flag is a reason to read the filing, not a verdict: many departures are planned retirements and many listing notices are resolved. Insider sales are shown for timing only; they are separate filings.
Insiders of Ovid Therapeutics reported 10 open-market purchases and 6 sales since 2017; purchases in 6 different years, most recently 2025.
| Year | Bought | Sold |
|---|---|---|
| 2026 | — | $29K2×2 trades |
| 2025 | $5K1×1 trade | $5.1K2×2 trades |
| 2024 | $50K1×1 trade | — |
| 2022 | — | $37K1×1 trade |
| 2021 | — | $126K1×1 trade |
| 2020 | $50K1×1 trade | — |
| 2019 | $5.32M4×4 trades | — |
| 2018 | $95K2×2 trades | — |
| 2017 | $110K1×1 trade | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Revenue
$0
−100.0% vs the same quarter a year earlier
Free cash flow, last 12 months
—
Cash from operations minus capital spending
Net debt
—
Debt —, cash $13.8M, at Sep 30, 2026
Net income, last 12 months
−$43.1M
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Nov 10, 2026.
Revenue and earnings history, 11 fiscal yearsEarnings dates and the stock's moves
Every annual report has a section where the company's managers explain the year's results (Item 7, Management's discussion and analysis). In this report it runs to about 6,000 words.
We are a biopharmaceutical company dedicated to developing small molecule medicines for brain disorders with significant unmet need. Our approach to achieve this goal is scientifically driven, patient-focused, and coupled with an integrated and disciplined approach to research, clinical development and business development. Our team has significant experience with and understanding of epilepsies and other neurological conditions, and we continue to gain insight into the ways the different molecular mechanisms and pathways underlying these disorders impact the symptoms patients experience.
And 10 more headings in the filing.
Source: SEC EDGAR, Form 10-K filed Mar 18, 2026. The quote is the opening of the managers' discussion, cut at a sentence; the word count is estimated from its length. Not investment advice.
Latest annual report filed Mar 18, 2026, compared with the one filed Mar 11, 2025. Read the filing
From time to time, we may become subject to various legal proceedings and claims that arise in the ordinary course of our business activities. We are not currently subject to any material legal proceedings.
Source: SEC EDGAR, Form 10-K filed Mar 18, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.
Off-exchange trading: 41.3% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (20.8% on ATS, 20.5% with other brokers), close to its 26-week average of 41.6%. Weeks of Sep 21 to Oct 16, 2026.
Largest ATS: INTELLIGENT CROSS LLC (14.0%), BIDS ATS (12.1%), UBS ATS (11.0%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
Last results
Nov 10, 2026
Within the 30 days after it, until Dec 10, 2026
Next results, expected
Mar 16, 2027
after the market closes; the date can move until the company confirms it
Purchases after results
70%
7 of 10 insider purchases since 2017 came within 30 days after a results announcement
From Ovid Therapeutics's own results filings (8-K Item 2.02) and its insiders' Forms 4 and 5. Many companies only let insiders trade in a period after results; OQRO does not know Ovid Therapeutics's policy and only shows the pattern in the filings. A purchase made long after results, at a company whose insiders usually buy right after them, is marked “Bought outside the usual window”.
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Insiders
Funds and stakes
Contracts, lobbying and filings
Company reports, price and press
Against the S&P 500 over the year
Who holds it
Things to keep in mind
Since Nov 18, 2025, OVID is up 66.7% and the index fund is up 4.5%: 62 points ahead of the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much OVID moves
Beta 1.4 (1 year vs SPY)
End-of-day prices. These figures describe the past year and say nothing about what comes next. Beta: how much the stock moved, on average, for each 1% move of the S&P 500 fund over 249 trading days (1 = in step with it).